jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Oct. 28, 2020

Mar. 30, 2022

jRCT2031200177

Post-marketing clinical trial of Pemafibrate in patients with impaired renal function

PALT02

Ishibashi Shun

Jichi Medical University

3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan

+81-3-3279-7454

ctrdinfo@kowa.co.jp

Sogabe Yukihisa

Kowa Company, Ltd.

4-14, Nihonbashi-honcho 3-chome, Chuo-ku, Tokyo

+81-3-3279-7454

ctrdinfo@kowa.co.jp

Complete

Aug. 27, 2020

Sept. 08, 2020
20

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

1) Dyslidemia : Fasting Serum TG>=150mg/dL
2) Renal dysfunction (A:eGFR<30mL/min/1.73m^2, B:Hemodialysis, C:30<=eGFR<60mL/min/1.73m^2)

1) Patients with severe liver damage, cirrhosis or biliary atresia patient
2) Patients with gallstones
3) Pregnant women or women who may be pregnant
4) Patients who have had a kidney transplant

20age old over
No limit

Both

Dyslidemia

0.1mg, twice a day, oral

Pharmacokinetic parameter (AUC)

Kowa Company, Ltd.
Review Board of Human Rights and Ethics for Clinical Studies
13-2 Ichibancho, Chiyoda-ku, Tokyo

+81-3-5213-0028

info@hurecs.org
Approval

July. 20, 2020

No

none

History of Changes

No Publication date
2 Mar. 30, 2022 (this page) Changes
1 Oct. 28, 2020 Detail